Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects by Julkunen, Heli et al.
ARTICLE
Leveraging multi-way interactions for systematic
prediction of pre-clinical drug combination effects
Heli Julkunen 1, Anna Cichonska 1,2,3, Prson Gautam 3, Sandor Szedmak 1, Jane Douat1,
Tapio Pahikkala 2, Tero Aittokallio 1,3,4,5,6✉ & Juho Rousu 1✉
We present comboFM, a machine learning framework for predicting the responses of drug
combinations in pre-clinical studies, such as those based on cell lines or patient-derived cells.
comboFM models the cell context-specific drug interactions through higher-order tensors,
and efficiently learns latent factors of the tensor using powerful factorization machines. The
approach enables comboFM to leverage information from previous experiments performed
on similar drugs and cells when predicting responses of new combinations in so far untested
cells; thereby, it achieves highly accurate predictions despite sparsely populated data tensors.
We demonstrate high predictive performance of comboFM in various prediction scenarios
using data from cancer cell line pharmacogenomic screens. Subsequent experimental vali-
dation of a set of previously untested drug combinations further supports the practical and
robust applicability of comboFM. For instance, we confirm a novel synergy between ana-
plastic lymphoma kinase (ALK) inhibitor crizotinib and proteasome inhibitor bortezomib in
lymphoma cells. Overall, our results demonstrate that comboFM provides an effective means
for systematic pre-screening of drug combinations to support precision oncology
applications.
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Combination therapies are often required for treatingcancer patients with advanced stages of the disease. Inaddition to overcoming monotherapy resistance, com-
binatorial treatments can also reduce toxicity of the treatment
(by reduced doses of the drugs) and improve therapeutic effi-
cacy (by multi-targeting effect)1–3. With recent advances in
high-throughput screening methods, a systematic evaluation of
combinations among large collections of chemical compounds
has become feasible. This typically leads to large-scale experi-
ments, in which the combinatorial responses are tested in
various doses of the individual compounds, resulting in
dose–response matrices that capture the measured combination
effects for every concentration pair in a particular sample (e.g.,
cancer cell line or patient-derived cells)4. However, even with
modern high-throughput instruments, experimental screening
of drug combinations quickly becomes impractical, as the
number of conceivable drug combinations increases rapidly
with the number of drugs in consideration. In addition, the
inherent heterogeneity of cancer cells pose further challenges
for the experimental efforts, as the combinations need to be
tested in various cell contexts and genomic backgrounds5,6.
Therefore, computational methods are often being used to
guide the discovery of effective combinations to be prioritized
for further pre-clinical and clinical validation7,8.
During the recent years, machine learning has emerged as a
powerful approach to aid the drug development process by
offering systematic means for the prediction of target bioac-
tivities and drug-induced effects9–13, thereby providing gui-
dance for drug discovery and repositioning efforts14,15. Until
recently, the performance of machine learning methods in
predicting drug combination effects was limited by the lack of
high-quality training data8. However, this is gradually changing
as increasing amounts of data from pre-clinical drug combi-
nation screens are becoming available, therefore creating new
opportunities also for the application of large-scale machine
learning methods4,5,16. For instance, the NCI-ALMANAC
dataset generated by the US National Cancer Institute (NCI)
provides over 3 million experimentally measured drug combi-
nation responses across various cell lines and tissue types4.
However, despite the potential value of such datasets, the high
dimensionality of the underlying dose–response data and the
inherent complexity of drug interaction patterns across various
doses pose challenges to accurate modeling of drug combina-
tion effects.
Several computational tools have been proposed for the pre-
diction of drug combinations2,7,8,17. Many of these tools have
been systematically benchmarked in two crowdsourced DREAM
Challenge competitions18,19, which demonstrated that computa-
tional predictions can achieve high accuracies for selected drug
classes, provided there are enough drug information and training
data available. However, the focus of these challenges and most of
the previously proposed methods has been on directly predicting
drug combination synergies (i.e., whether the combined summary
effect is higher than expected). In many practical applications,
however, more detailed information on dose–response effects of
the combinations is required, rather than simply classifying the
summary effects into synergistic or antagonistic classes. Fur-
thermore, as noted in the recent AstraZeneca-Sanger drug com-
bination prediction DREAM challenge19, the performance of the
computational methods typically relies on selective incorporation
of target features and biological knowledge that is not always
available for all drugs and cell models. Therefore, there is a need
to develop integrative and robust models capable of generalizing
and learning from large amounts of available data that facilitate
the exploration of the extensive combinatorial drug and dose
spaces.
Here, we present comboFM, a novel machine learning frame-
work for systematic modeling of drug-dose combination effects in
a cell context-specific manner. It is generally applicable to any
pre-clinical model systems, such as patient-derived primary cells,
but we demonstrate its performance here in cancer cell lines
(Fig. 1). We base our work on the observation that the drug
combination dose–response data can be compiled into a higher-
order tensor indexed by drugs, drug concentrations, and cell lines.
comboFM then models the cell line-specific responses to a
combination of drugs as an interaction between the different
modes of the tensor using a higher-order factorization machine
(FM)20, a recently proposed machine learning approach for non-
linear learning on large data. FMs have been shown to be com-
pelling tools with the ability to work particularly well with high-
dimensional and sparse datasets20–22. In contrast to existing
machine learning models, comboFM enables one to explore the
detailed landscape of drug combination responses across various
doses. We demonstrate that comboFM obtains high prediction
accuracy in various practical application scenarios, significantly
outperforming other approaches. Furthermore, we show the
robustness and practical potential of comboFM by experimentally
validating untested drug combinations predicted for specific cell
lines.
Results
Overview of comboFM model. comboFM was developed for
predicting drug combination responses of cancer cell lines in
three practical scenarios (Fig. 1a). The first scenario of predicting
new dose–response matrix entries corresponds to filling in the
gaps in partially measured dose–response matrices. In the second
scenario of new dose–response matrix inference, the predictions
are made for completely held out dose–response matrices of
untested drug–drug–cell line triplets, such that the drug pair has
still been observed in other cell lines. In the third and most
challenging scenario of new drug combination inference, the
predictions are made for completely new drug combinations with
no available combination measurements in any cell line, thereby
providing guidance on repositioning of the drugs for new com-
binations and cell contexts.
To capture the high-order interactions between drug combina-
tions in different cell lines and at various doses, comboFM models
the multi-way interactions between the two drugs, the cell lines
and the dose–response matrices as a fifth-order data tensor X
(Fig. 1b). Furthermore, comboFM makes it possible to integrate
any auxiliary data of the drugs and cell lines, such as chemical
descriptors in the form of molecular fingerprints of drug
compounds, gene expression profiles of the cancer cell lines and
concentration values tested for the drugs.
For the learning algorithm, the data tensor X is flattened into a
two-dimensional array (Fig. 1c), where each row vector x
identifies a single entry in the original tensor. Given the
associated responses yi in the training data, comboFM model is
learned using factorization machines (FMs). Higher-order FMs
learn a non-linear regression model from the input features (x) to
the output (y) by estimating a regression weight wi1;:::;it for each
combination of input features xi1  xi2    xit , where t is the order
of the interaction. However, instead of estimating the weights
wi1;:::;it separately as in polynomial regression, FMs approximate
the weights using factorized parametrization (Fig. 1d), where the
weights are coupled through multiplication of latent factors
learned by the FM. This approach avoids the computational and
statistical problems that would result from directly estimating the
weight tensor W. In addition, the coupling of the weights allows
effective learning in situations where the data tensor is sparsely
populated.
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Fig. 1 Overview of the comboFM framework for the prediction of drug-dose combination effects. a Three prediction scenarios are considered: filling in
missing entries in partially tested dose–response matrices, predicting a complete dose–response matrix in a new cell line, and making predictions for a
completely new drug combination not tested so far in any cell line. b In each prediction scenario, the experimentally measured dose–response matrices are
compiled into a fifth-order tensor X indexed by drugs (D1, D2), drug concentrations ([D1], [D2]) and cell lines (C), and genomic and chemical descriptors are
integrated into the prediction model. c The structure of the tensor underlying the drug combination dose–response matrix data is one-hot encoded into a
single feature matrix together with the additional chemical and genomic descriptors. d The model parameters wi1 ;i2 ;¼ ;it , for a tth order combination (t= 3
depicted) of features i1, …, it are approximated using factorized parametrization wi1 ;i2 ;¼ ;it 
Pk
s¼1 p1sp2s ¼ pts (see “Methods”). d denotes the total number
of features and k is a hyperparameter defining the rank of the factorization.
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Accurate drug combination response predictions by comboFM.
To systematically evaluate the comboFM model, we used the
anticancer drug combination response data from the NCI-
ALMANAC study4. To enable various splits of data into dif-
ferent cross-validation folds as required by the different pre-
diction scenarios and to keep the computational complexity
manageable, we considered a subset of the data consisting of 50
unique FDA-approved drugs (Supplementary Table 3) in 617
distinct combinations screened in various concentration pairs
across all the 60 cell lines originating from 9 tissue types23. In
this data subset, a total of 333,180 drug combination response
measurements and 222,120 monotherapy response measure-
ments of single drugs are available in the form of percentage
growth of the cell lines (see “Methods”). To computationally
quantify the performance of comboFM in predicting drug
combination responses and optimize the model parameters, we
performed a 10 × 5 (10 outer folds, 5 inner folds) nested cross-
validation (CV) procedure under the three prediction scenarios
(see “Methods”). The order of the feature interactions modeled
by the FM was set to m= 5, according to the order of the
underlying tensor.
To investigate the benefit of considering higher-order feature
interactions, we also performed experiments using both second
order formulation of FMs and first order FMs (corresponding to
ridge regression). To further benchmark the predictive perfor-
mance of comboFM, we applied random forest (RF) as a
reference model, a widely-used machine learning model that is
based on a rather different learning principle, and has previously
been used for modeling drug combination effects24–28, including
the winning method of the recent AstraZeneca-Sanger drug
combination prediction DREAM Challenge19. The cross-
validation folds were held fixed throughout the experiments to
ensure a fair comparison. We assessed the predictive performance
of the methods using root mean squared error (RMSE), as well as
Pearson and Spearman correlation between original and pre-
dicted dose–response matrices.
By leveraging the multi-way interactions present in the
underlying high-dimensional drug combination space across
drugs, drug concentrations, and cancer cell lines, the 5th order
comboFM demonstrated high predictive accuracy in all the three
prediction scenarios (Fig. 2), outperforming the random forest
reference (p < 10−10 in all prediction scenarios, two-sided
Wilcoxon paired signed rank sum test, N= 666,360). In the
scenarios of predicting new dose–response matrix entries and
new dose–response matrices, the 5th order comboFM obtained a
Pearson correlation of 0.97, and even in the new drug
combination prediction scenario, the 5th order comboFM
obtained a Pearson correlation of 0.95. The 5th order comboFM
was also markedly more accurate than both the 1st- and 2nd
order comboFMs in all the three scenarios. Similar relative
performance of the methods was also observed using Spearman
correlation and RMSE (Fig. 2). In addition, the distribution of the
predictions by 5th order comboFM followed that of the measured
responses most accurately (Supplementary Fig. 1).
In addition to the global predictive performance of the
methods, we analyzed also their performance in different tissue
types and across the various types of drug combination therapies
(Fig. 3 and Supplementary Figs. 2–4 and Supplementary Table 1).
In all the three prediction scenarios (Fig. 3a–c), comboFM
showed the highest average prediction accuracy in each of the
tissue types, and also the smallest variance across the tissue types.
The combination response in colon cancer appeared marginally
more difficult to predict than the other tissue types, which is likely
explained by higher variation in the colon cancer response data,
as the number of colon cancer cell lines was similar to the other
tissue types and thus the marginally inferior performance is
unlikely to stem from limited data quantity. Nevertheless, the 5th
order comboFM was still the most accurate method also in colon
cancer cell lines. Furthermore, comboFM was shown to provide
high accuracies across various types of combination therapies
(chemotherapies, targeted therapies, and other therapies, such as
hormonal therapies) (Fig. 3d–f). The combination therapies
involving drugs from the Other class include the smallest number
of observations, explaining their reduced predictive accuracy with
all the methods.
To further validate the performance of the 5th order
comboFM, we also evaluated its predictive accuracy in the
remaining part of the NCI-ALMANAC data that was not used in
the cross-validation, consisting of 4737 distinct drug combina-
tions. The model was trained on the full development dataset of
617 drug combinations as well as the monotherapy responses of
the single drugs in the validation set, and the trained model was
then used for predicting responses of the 4737 drug combinations
in the validation set across the various cell lines. 5th order
comboFM demonstrated high predictive accuracy also in this
validation set (Supplementary Figs. 5 and 6), with Pearson
correlation of 0.91 even for combinations where neither drug had
previously been observed in any other combination, i.e. only the
monotherapy responses of the individual drugs in the combina-
tion were available to the model.
Synergy scores can be recovered with high accuracy based on
the predicted dose–response matrices. As the interest in drug
combination experiments often lies in discovering the most
synergistic drug combinations, we also quantified drug combi-
nation synergies based on the dose–response matrices predicted
with comboFM. As a synergy quantification model, we applied
NCI ComboScore (see “Methods”)4, computed over the complete
predicted dose–response matrices. Although drug combinations
with an NCI ComboScore above zero are technically defined to be
synergistic, combinations with highly synergistic effects are
typically considered as more attractive candidates for further
experimental validation. Therefore, we labeled the extreme
synergistic drug combinations (observed NCI ComboScore value
in the top 10%) as the positive class and the remaining combi-
nations, including lowly synergistic, additive, and antagonist
combinations, as the negative class.
Drug combination synergy scores were recovered with a high
accuracy from the dose–response matrices predicted by the 5th
order comboFM in all three prediction scenarios, significantly
outperforming the other compared methods (Supplementary
Fig. 7). Importantly, the drug combination synergies could be
accurately computed based on the predicted dose–response
matrices using 5th order comboFM even in the challenging
scenario of predicting new drug combinations, with a Pearson
correlation of 0.72 (p < 10−10, two-sided t-test, N= 74,040)
between the observed and predicted NCI ComboScores. In the
task of discriminating highly synergistic drug combinations, the
5th order comboFM obtained a high area under the receiver
characteristic operator curve (AUC) of 0.91 in the new drug
combination prediction task (Supplementary Fig. 8). The
discrimination accuracies were at high level in each prediction
scenario, and when using various top-% extreme synergy
combinations (Supplementary Fig. 8).
Experimental validation of the most synergistic predicted drug
combinations. To further demonstrate the ability of comboFM
to predict novel and robust drug combinations, the model was
trained using all the available dose–response measurements in
the development dataset, and the trained comboFM was then
used to predict dose–response matrices for remaining
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unmeasured drug combinations across all the 60 cell lines,
which resulted in a total of 10,320 predicted complete
dose–response matrices. Experimental validation was per-
formed subsequently on a subset of 16 drug combinations
specific for 4 cell lines (Supplementary Table 2), where high
synergy was predicted by comboFM. These combinations were
selected to mainly involve molecularly targeted therapies, as the
recent interest has increasingly evolved toward targeted agents
over the standard cytotoxic chemotherapies. In particular, we
focused on cancer-specific drug combinations which were
predicted to have highly synergistic effects only in a subset of all
the cell lines and tissue types. This poses a more challenging
task than identifying broadly toxic combinations that kill most
cancer cells, but which may also induce severe toxicities in the
healthy cells. As in the previous experiments, we considered as
highly synergistic those combinations with an observed NCI
ComboScore values in the top 10% in a particular tissue type.
The results of the experimental validation of 16 drug–drug–cell
line triplets are summarised in Fig. 4, using the Bliss model to
quantify the observed synergy. The background histogram shows
a distribution of an in-house drug combination dataset, consisting
of 60 drug combinations tested against 16 KRAS-mutants
pancreatic ductal adenocarcinoma cell lines. Since the combina-
tions in the reference set were not randomly-selected, the
background synergy distribution shows a slight positive bias;
however, since the assay was the same as the one used for the
experimental validation of comboFM predictions (“Methods”), it
is expected to provide a valid reference distribution for statistical
evaluations. All the drug combinations predicted by comboFM
were validated as synergistic, when considering positive Bliss
score as evidence for a degree of synergy (p < 10−4, binomial test
against the background distribution). Importantly, 9 out of 16
combinations had a Bliss synergy score higher than 90% of the
background distribution (p < 10−5, binomial test). In addition to
Bliss synergy score, we also computed the synergy scores using
three other popular synergy models: Loewe, highest single agent
(HSA) and zero-interaction potency (ZIP) scores (Supplementary
Figs. 9 and 10). These results demonstrate the robustness of the
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Predicting new dose–response matrix entriesa
comboFM-5 comboFM-2 comboFM-1 RF
Predicting new dose–response matricesb
comboFM-5 comboFM-2 comboFM-1 RF
Predicting new drug combinationsc
Fig. 2 Predictive performance of 5th (comboFM-5), 2nd (comboFM-1) and 1st order comboFM (comboFM-1), and random forest (RF) as scatter plots
between the measured and predicted dose–response matrices. The responses were measured by percentage growth in the three prediction scenarios:
a new dose–response matrix entries, b new dose–response matrices, and c new drug combinations. Root mean squared error (RMSE), Pearson correlation
(RPearson) and Spearman correlation (RSpearman) for the drug combination response prediction are reported as averages over 10 outer CV folds. The
Pearson correlation of the NCI ComboScores is reported as an average over all computed NCI ComboScores, computed based on the predicted
dose–response matrices. Trend line and its equation are shown for each scatter plot.
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Fig. 3 Predictive performance of 5th (comboFM-5), 2nd (comboFM-2) and 1st order comboFM (comboFM-1), and random forest (RF) across tissue
types and drug classes in the three prediction scenarios. a–c tissue types. d–f drug classes. The three prediction scenarios are depicted as follows:
a, d predicting new dose–response matrix entries, b, e predicting new dose–response matrices, and c, f predicting new drug combinations. Further
information on the drug classes can be found in Supplementary Table 3. In the boxplots, the horizontal lines drawn in the middle denote the median, and
the lower and upper hinges correspond to the 25th and 75th percentiles, respectively. The upper and lower whiskers denote the largest and smallest
values, respectively, no further than 1.5 times the inter-quartile range (IQR). The points that are not included between the whiskers are outlier predictions.
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Among others, comboFM predicted a particularly high level of
synergy for the combination between anaplastic lymphoma
kinase (ALK) inhibitor crizotinib and proteasome inhibitor
bortezomib in lymphoma cell line SR. In addition to our in-
house experimental validations, this finding was further validated
in external measurements in the NCI-ALMANAC data that were
not used as part of comboFM training data. The ALK inhibitors
are effective against cancers harboring ALK fusions. The SR cell
line carries the NPM1-ALK fusion, which is the first ever
discovered ALK fusion in large-cell lymphoma29. Bortezomib is
approved for mantel cell lymphoma supporting its potential in
lymphoma treatment. It is likely that two even mildly effective
inhibitors when used in combination may enhance the inhibition
effect and potentially overcome monotherapy resistance. Notably,
comboFM made this prediction without knowledge of the ALK
fusion status of the SR cell line, i.e., this biological rationale was
not available for the model. The prediction of high synergy
between the first-generation inhibitors of ALK and proteasome
for lymphoma cell lines highlights the potential of comboFM to
predict biologically plausible combination effects.
The comboFM model identified also another unique drug
combination effective against the SR cell line, the combination of
EGFR inhibitor gefitinib with an approved chemotherapy
lomustine for lymphoma treatment. One of the mechanisms
inducing resistance to ALK inhibitors is activation of EGFR, as
they signal through similar downstream pathways. Brigatinib, a
dual ALK/EGFR inhibitor, is therefore being explored in clinical
settings against lymphoma and lung cancer patients
(NCT01449461). Our comboFM method predicted combination
partners to extensively explored ALK and EGFR inhibitors for
lymphoma, which we were able to also validate in the
experimental setting (Fig. 4). These examples show the potential
of comboFM to identify novel combinations of both targeted and
cytotoxic treatments, that individually are already used as
lymphoma treatments, and therefore are likely to have acceptable
toxicity profiles in clinical applications.
Discussion
Given the enormous number of conceivable drug and dose
combinations, computational approaches are needed to accelerate
the experimental work by providing guidance toward identifying
the most promising drug combinations for further experimental
validation. While large datasets of drug combination
dose–response matrices have already been tested in the lab,
extensive gaps still remain in the combinatorial space among both
targeted and non-targeted therapies, as well as hormonal and
immunotherapies. Here, we have presented a novel machine
learning framework, comboFM, for large-scale systematic pre-
diction of drug combination effects in human cancer cell lines.
The obtained results demonstrate that comboFM can leverage
predictive higher-order relationships between drugs, drug con-
centrations, and cancer cell line responses, which were missed
when using random forest and simpler approaches, including 1st
and 2nd order formulation of comboFM. Importantly, comboFM
can accurately generalize the predictions also for new drug
combinations not observed in the training space, which enables
one to systematically predict dose–response matrices also for so
far untested drug combinations formed by the individual drugs in
the training set. This will provide guidance on repositioning the
drugs into new combinations. We also demonstrated that com-
boFM consistently obtains high prediction performance across
various tissue types and classes of drug combination therapy. In
addition, 5th order comboFM was 3 times faster to train com-
pared to the random forest reference when run on the same CPU
and considering relatively conservative amount of 200 training
epochs for training the comboFM model (Supplementary
Table 2). Further performance advantages were obtained by
employing a GPU for training the 5th order comboFM model (34
times faster compared to random forest).
Modeling the drug combination effects first at the level of
dose–response matrices and subsequently quantifying the level of
overall drug combination synergy over the full matrix provides
many benefits compared to approaches that directly aim at pre-
dicting the drug combination synergies. First of all, predicting the
underlying dose–response matrices enables one to leverage all the
information contained in the dose–response matrices and pro-
vides detailed information of the response landscape across var-
ious dose combinations. In addition, in the second stage, one is
not limited only by a single synergy quantification model, but can
explore the synergies using various models, hence gaining a more
































Experimentally tested combinations selected based on comboFM predictions
Everolimus - Romidepsin - MALME-3M
Romidepsin - Vismodegib - MALME-3M
Lomustine - Gefitinib - SR
Cladribine - Romidepsin - MALME-3M
Erlotinib - Axitinib - IGROV1
Teniposide - Lenalidomide - SR
Dactinomycin - Romidepsin - MALME-3M
Crizotinib - Bortezomib - SR
Oxaliplatin - Romidepsin - MALME-3M
Gefitinib - Vismodegib - MALME-3M
Fulvestrant - Crizotinib - SR
Thioguanine - Megestrol acetate - SR
Romidepsin - Everolimus - HS578T
Lomustine - Gefitinib - IGROV1
Vandetanib - Exemestane - IGROV1
Vismodegib - Romidepsin - HS578T
50% 75% 90% 99%
Fig. 4 Measured drug combination synergy scores in the experimental validation. In-house experimental validation of 16 selected predictions in specific
cell lines are shown as colored lines (on top), and the histogram shows a background distribution from in-house reference dataset that comprises of 60
drug combinations tested against 16 KRAS-mutants pancreatic ductal adenocarcinoma cell lines (see “Methods”). The synergy was quantified using Bliss
independence score for the most synergistic area of the dose–response matrix (see Supplementary Fig. 9 for other synergy scores). The color scale
corresponds to the Bliss scores (green—antagonistic response, white—independent response, red—synergistic response). Dashed lines denote the
percentiles of the background distribution obtained using the same experimental setup.
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landscapes30. Furthermore, understanding the drug combination
effects both at the dose level as well as at the synergy level pro-
vides useful guidance for precision medicine efforts. For instance,
combination synergies observed at lower doses are often better
tolerated in the clinical practice. Furthermore, it has been shown
that for most of the FDA-approved drug combinations, only little
evidence of additivity or synergy was observed in pre-clinical
models31, highlighting that synergy is not always needed for
clinical treatment success. However, it has also been argued that
patient stratification based on predictive markers is likely to
reduce variability in clinical therapy responses, and contribute to
achieving truly synergistic responses to combination
treatments32.
In-house experimental validations of the top-synergistic combi-
nations predicted using the NCI-ALMANAC data demonstrated
that the comboFM predictions are robust also to the experimental
setup. The in-house assay had many experimental differences when
compared to the combination assay used to profile the NCI-
ALMANAC development dataset. In particular, the in-house assay
measured the drug combination responses in the form of percen-
tage inhibition, instead of percentage growth that is used in the
NCI-ALMANAC assay. Therefore, we could not calculate the NCI
ComboScore for the experimental validations, but instead scored
the combinations using four popular synergy models (Supple-
mentary Figs. 9 and 10). As an example, comboFM predicted a
pivotal role of histone deacetylase (HDAC) in melanoma cell line
MALME-3M, thereby suggesting potential of HDAC inhibition
against melanoma. In particular, various combinations with HDAC
inhibitor romidepsin were predicted to be effective against BRAF-
mutants melanoma cell line MALME-3M, which also held true in
the experimental settings (Fig. 4). Even though most of the drugs in
the romidepsin-combinations have already been explored in dif-
ferent combinations to target melanoma33,34, the combinations
predicted by comboFM have remained unexplored against mela-
noma, and warrant further investigation. Individually, each of these
inhibitors have shown promising results in pre-clinical or clinical
settings against melanoma, further supporting their use in combi-
nation therapies.
Even though the main objective of this work was to develop
and carefully validate the comboFM model in cancer cell lines as
an accurate methodology for systematic prediction of drug
combination responses for biological discovery, we note that
many of the drugs identified by comboFM have been or are
currently being explored in clinical settings against the specific
cancer type, either as single agents or in combination with other
drugs (see Supplementary Table 5). For instance, HDAC inhibitor
vorinostat is being tested against BRAF-mutant advanced mela-
noma in an ongoing clinical trial (ref. 35; NCT02836548). Simi-
larly, mTOR inhibitor everolimus is shown to selectively target
BRAF-mutant melanoma in acidic condition36. In an ongoing
clinical trial, mTOR inhibitors everolimus or temsirolimus in
combination with BRAF inhibitor are being investigated against
BRAF-mutant advanced solid tumors (NCT01596140). SMO-
inhibitor vismodegib blocks Hedgehog pathway which regulates
the skin growth. In case of medulloblastoma, HDAC inhibitors
are active against even SMO-inhibitor resistant cell lines37.
Hence, concurrent use of HDAC- and SMO- inhibitors holds a
promising strategy to target melanoma, as predicted by romi-
depsin and vismodegib combination (Fig. 4). In the same line of
rationale, combining HDAC inhibitor with DNA damaging
agents, such as oxaliplatin, dactinomycin, and cladribine, holds
strong promises and are explored in different pre-clinical and
clinical settings33,34,38,39.
These case examples already unveil the potential of our method
for predicting combinations with translational potential, although
these findings warrant further validation in proper clinical trials.
Furthermore, once the model accuracy has been confirmed in the
cell line resources, we envision that the carefully validated model
will be applicable also to data from individual cancer patients,
thereby providing means for tailoring effective combinations in
precision oncology applications. For selected cancer types, such as
haematological malignancies, molecular and drug response pro-
filing data are becoming available from patient-derived primary
cells that can be used for training cancer type-specific prediction
models40,41. Once similar data from other cancer types becomes
available, comboFM will enable also pan-cancer analyses, similar
to the current analyses in the NCI-ALMANAC cell lines. We
found that many of the combinations predicted in the NCI-
ALMANAC cell lines have actually already been tested in clinical
trials (Supplementary Table 5). Interestingly, most of the com-
binations are tested in different indications than what was pre-
dicted based on the cell lines, suggesting further drug repurposing
opportunities. The comboFM predictions require input data that
start to be routinely available in many functional precision
medicine studies, making it therefore broadly applicable for many
cancer types and therapy classes.
In the present study, we assumed that one knows the
monotherapy responses of single drugs prior to predicting the
combination responses, as in practice it is often needed to know
the concentration ranges and potencies of the single drugs (i.e.,
dose–response curves) in order to know which dose combina-
tions should be used in combination testing, and also how
potent the compounds are individually. comboFM strongly
benefits from this information due to its capability to inter-
polate in the space of dose–response matrices through the
computation of latent factors representing similarly behaving
drug combinations from the response tensor alone (similarly to
recommender systems grouping users by the movies they have
liked in the past), while the drug and cell line descriptors
merely fine-tune the predictions. It is plausible that by careful
experimental design, one could minimize the number of
monotherapy responses needed for accurate dose–response
matrix prediction42 whilst maintaining the accuracy of the
comboFM model, which we leave as an interesting future
research topic. However, in a scenario where one would like to
perform predictions for completely new molecules with no
prior monotherapy or combination response data in any cell
line, the computed latent factors are no longer helpful, and
none of the methods could perform well with the current design
(Supplementary Fig. 13). This limitation of the methodology in
such scenarios could potentially be addressed by more extensive
feature engineering or by developing models that are specialized
for the case of predicting dose–response matrices for combi-
nations of completely new drugs.
As with any high-throughput pre-clinical data, the cell line
drug response profiles may show inconsistency in experimental
outputs across the same cell line-treatment pairs43. Therefore, we
argue that it is important to develop and initially evaluate the
prediction models in large enough and standardized cell line
resources, such as NCI-ALMANAC, to avoid any reproducibility
issues in the development phase. We further tested the model
predictions using distinct experimental setups in the same cell
lines to show that the predictions were robust enough against
such biological and technical variability.
In conclusion, given the high cost of the experimental
screening of drug combinations, comboFM has the potential to
provide time- and cost-effective means toward prioritizing the
most promising drug combinations for further pre-clinical or
clinical studies. The accurate and robust drug combination
response predictions provide a promising approach to streamline
the development and expansion of combination therapeutics in
personalized cancer treatment. This could ultimately accelerate
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the clinical use of combination therapeutics to combat acquired
drug resistance and to increase therapeutic efficacies.
Methods
Higher-order factorization machines. comboFM uses higher-order factorization
machines (HOFM)20,21 for predicting the drug–drug combination responses.
HOFMs are non-linear regression models learned with a training set of examples
fðx1; y1Þ; ðx2; y2Þ; :::; ðxn; ynÞg
of feature vectors x 2 Rd and output labels y 2 R.
A trained HOFM models the output y 2 R as a function of single, pairwise, and






1≤ i < i0 ≤ d
wi;i0xixi0 þ :::þ
X
1≤ i1 < :::< im ≤ d
wi1 ;i2 ;im  xi1xi2 :::xim :
ð1Þ
The first term corresponds to a linear model, and all parameters wi are
independently estimated. The higher-order parameters are, on the other hand,
estimated in a factorized form
wi;i0 ¼ hpð2Þi ; pð2Þi0 i ð2Þ
wi1 ;i2 ;it ¼ hp
ðtÞ
i1
; pðtÞi2 ; ¼ ; p
ðtÞ
it
i; t ¼ 3; ¼ ;m ð3Þ
where pmi 2 Rk denotes the mth order factor weight of feature i, k is the
hyperparameter defining the rank of the factorization, and
ha1; a2; ¼ ; ami ¼
Xk
s¼1
a1sa2s    ams ð4Þ
denotes a generalized inner product of m vectors ai 2 Rk; i ¼ 1; ¼ ;m that
generalizes the usual pairwise inner product 〈a, b〉= aTb to sets of m vectors.
The factor weights are collected into matrices PðmÞ ¼ ðpm1 ; ¼ ; pmd ÞT 2 Rd ´ k .
The factorized parametrization drastically reduces the number of estimated
parameters from O(dm) (all feature combinations have their own parameter) to O
(kdm) (m− 1 factor matrices of dimension d × k). In principle HOFMs allow an
unique rank kt for each order t = 2, ..., m. In the above description and in our
experiments, we used uniform rank k= k2 =…= km.
FMs are based on the assumption that the effect of pairwise and higher-order
feature interactions has a low rank and allows FMs to estimate reliable parameters
even under highly sparse data. Hence, the co-occurrence of xi and xi0 does not need
to be observed in order to learn wi;i0 : the factors pi0 : and pi0 : can be learned by
interacting with other dimensions and the dot product of pi0 : and pi0 : still gives wi;i0 .
This is extremely useful in the case of high-dimensional drug combination data
where the input tensor is typically very sparse, and thus allows to make reliable
inferences of the responses to new drug combinations whose individual
components have still been observed in other combinations elsewhere in the
training tensor. Compared to standard matrix factorization approaches, FMs
provide additional flexibility by allowing integration of auxiliary data describing the
drugs and cell lines, such as chemical and genomic descriptors.
The objective function of learning higher-order factorization machines is to















where β1, . . . , βm > 0 are regularization parameters. To limit the number of
hyperparameter combinations to search, following the work by Blondel et al.20, we
set β1= . . .= βm, and a uniform rank k= k2= . . .= km. In the experiments, we
used a recent TensorFlow implementation of higher-order factorization
machines44.
On the NCI-ALMANAC data, increasing the order and rank of the
factorization machine both improve the predictive performance (Pearson
correlation) of the comboFM model (Supplementary Fig. 12). The predictive
performance increases steeply until order 5, which matches the intrinsic order of
the data tensor X (See Fig. 1b), and then continues to increase more slowly. The
performance increase due to increasing rank of the factorization is rapid until
around rank 50 and then continues to increase more slowly. There is no apparent
overfitting even with factorization order as high as 10 and rank as high as 150.
Synergy quantification. As the interest often lies in discovering the most syner-
gistic drug combinations, we quantify the drug combination synergies based on the
predicted dose–response matrices. To compute the synergy scores, we apply the
NCI ComboScore, which was introduced along with the NCI-ALMANAC dataset4,
originally modified from the Bliss independence score.
The NCI ComboScore for drug A and drug B is defined as the sum of the





ðycðAp;BqÞ  yeðAp;BqÞÞ ð6Þ
where yc(Ap, Bq) is the combination growth fraction of the cell line exposed to
drug A in concentration p and drug B in concentration q, and ye(Ap, Bq) is the
expected growth fraction for the combination defined based on the monotherapy
effects of drug A and drug B as follows:
yeðAp;BqÞ ¼
minðymðApÞ; ymðBqÞÞ if ymðApÞ≤ 0 or ymðBqÞ≤ 0
1
150 ð~ymðApÞ  ~ymðBqÞÞ otherwise
(
ð7Þ
where ym(Ap) and ym(Bq) denote the monotherapy effects of drug A in
concentration p and drug B in concentration q, respectively. We applied ~ym ¼
minðym; 150Þ that truncates the growth fraction at 150, with the threshold
selected based on the histogram of the measured drug combination responses
(Supplementary Fig. 11).
Training setup. In order to evaluate the predictive performance and optimize the
model parameters under the three prediction scenarios, we performed a 10 × 5 (10
outer folds, 5 inner folds) nested cross-validation procedure. For all the factor-
ization machine models, the rank parameter was optimized in the range k=
{25, 50, 75, 100} and the regularization parameter in the range β=
{102, 103, 104, 105}. The order of the modeled feature interaction was set to 5
according to the order of the underlying tensor, as a compromise between the
training time and prediction accuracy. The learning rate was set to 0.001 based on
preliminary experiments and other parameters were kept in their default values.
The number of trees of the random forest model was optimized in the range
{32, 64, 128, 512} and the fraction of features considered when looking for the best
split (MaxFeatures) in the range {0.25, 0.5, 0.75, 1.0}.
As each input sample is represented by a single feature vector, in order to take
the symmetry of the drug combinations into account, the samples were duplicated
such that both of the drugs in a combination were included in both positions in the
feature vectors. This informs the algorithm that the combination of drug A with
drug B should be considered the same as the combination of drug B with drug A.
The prediction accuracy of all the models was assessed using the same performance
evaluation metrics: RMSE, Pearson correlation, and Spearman correlation.
Evaluation of the prediction performance. In this type of applications, the pre-
dictive performance is significantly affected by whether the training and test sets
share the different components of the modeled interactions, and it is thus
important to reliably quantify the prediction accuracy under practical application
scenarios. Therefore, we evaluated the predictive performance of comboFM under
three prediction scenarios: (a) new dose–response matrix entry prediction, (b) new
dose–response matrix prediction and (c) new drug combination prediction (c.f.
Fig. 1). For each scenario, we used dedicated nested cross-validation setups to
ensure unbiased evaluation. In scenario (a), the predictions were made for indi-
vidual held-out entries in dose–response matrices. The held-out entries were
selected at random for each cross-validation fold. In scenario (b), the predictions
were made for completely held out (dose–response matrix, cell line) pair, such that
the same drug combination had still been measured in other cell lines. This sce-
nario corresponds to a widely-used strategy in other computational works con-
cerning drug combination synergy prediction, in which the predictions are made
for new drug–drug-cell line triplets. In scenario (c), most challenging scenario of
new drug combination prediction, the predictions are made for novel drug com-
binations outside the training space with no available combination measurements.
In all prediction scenarios, we assumed that the monotherapy responses of the
single drugs in the combination are known.
To computationally evaluate the prediction performance and optimize the
model parameters, we performed a nested cross-validation procedure. In the first
prediction scenario of new dose–response matrix entry prediction, the cross-
validation folds were formed by simply random sampling from the tensor entries.
In the second prediction scenario concerning new dose–response matrices, the
folds were created by randomly sampling on the level of dose–response matrices,
i.e., if a drug pair-cell line triplet (xd1 ,xd2 ; xc) belonged to the test set, the training
tensor did not include any entry involving the triplet (xd1 ,xd2 ; xc). In the third
scenario of new drug combination prediction, the random sampling was performed
on the level of drug pairs and all the entries involving the test drug pairs were held
out from the training set, i.e., if a drug pair (xd1 ,xd2 ) belonged to the test set, the
training tensor did not contain any entry involving the pair (xd1 ,xd2 ). Furthermore,
we ensured that the individual drugs in the left out drug pairs are still observed
individually in other combinations in the training set, which enables the model to
learn from the way the individual drugs in the held out combinations act in other
combinations.
Drug combination anticancer activity dataset. The drug combination anticancer
activity dataset was obtained from a recent NCI-ALMANAC study4, which is the
largest available drug combination dataset to date. The original dataset covers over
5000 combinations of roughly 100 small molecule drugs screened against 60 cell
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lines in various concentrations, containing over 3 million response measurements.
The drugs included in the dataset are FDA-approved oncology drugs with proven
activity and established safety profiles. The cell lines represent human tumor cell
lines from the NCI-60 panel, originating from 9 different tissue types.
To reduce the computational complexity, we selected a subset of the NCI-
ALMANAC dataset by randomly sampling 50 drugs (Supplementary Table 3) from
the original set of drugs, ensuring that the distribution of the subset of drug
combination responses matched to that of the original one. Furthermore, we
selected drug combinations for which complete measurements across all the 60 cell
lines were available. As a result, we obtained a dataset for our experiments
consisting of 617 drug combinations of 50 unique drugs, screened in 45 unique
concentrations against 60 cell lines, containing 333,180 response measurements for
combinations and 222,120 measurements for monotherapies, measured by
percentage growth of the cell line with respect to a control. Each drug combination
in the dataset had been screened using 4 × 4 dose–response matrix design.
Data representation. Defining an informative input feature representation of the
underlying data is essential to take the full advantage of comboFM and FMs in
general. By defining appropriate input features, FMs have been shown to have the
representation power encompassing a variety of matrix and tensor factorization
models from standard models to more specialized ones21,22. Hence, by learning
FMs, all the subsumed factorization models can also be learned.
In order to represent the structure of the tensor underlying the drug combination
response data as single input feature vectors, one-hot encoding is used. Here, the
input feature vectors x are divided into five different groups corresponding to the
different modes of the tensor: two sets of drugs, their concentrations, and a cell line. In
each group, exactly one value is set to 1 and the rest to 0, with 1 denoting the instance
that is present in the corresponding interaction:
x ¼ 0; :::; 0; 1; 0; :::; 0|fflfflfflfflfflfflfflfflfflfflfflffl{zfflfflfflfflfflfflfflfflfflfflfflffl}
jDrugsj
0; :::; 0; 1; 0; :::; 0|fflfflfflfflfflfflfflfflfflfflfflffl{zfflfflfflfflfflfflfflfflfflfflfflffl}
jDrugsj
0; :::; 0; 1; 0; :::; 0|fflfflfflfflfflfflfflfflfflfflfflffl{zfflfflfflfflfflfflfflfflfflfflfflffl}
jConcentrationsj
0; :::; 0; 1; 0; :::; 0|fflfflfflfflfflfflfflfflfflfflfflffl{zfflfflfflfflfflfflfflfflfflfflfflffl}
jConcentrationsj






As the feature vector is non-zero only for the pair of drugs, drug concentrations,
and cell line present in the corresponding interaction, all the other interactions in the
FM model vanish and the model corresponds to standard factorization models
involving categorical variables. However, whereas standard factorization models are
limited to categorical input data only, comboFM and FMs can also incorporate
auxiliary features in addition to the information of the interacting elements, which can
further aid the prediction task, particularly when making predictions outside the
training space. In this work, we used chemical descriptors of molecules and genomic
descriptors of cell lines (see below for details).
Chemical descriptors. As chemical descriptors, we integrated molecular finger-
prints, binary vectors which are designed to represent the structure of a molecule as
a series of bits, each one representing the presence or absence of a particular
substructure. We selected a popular fingerprint of type ‘estate’, consisting of 79 bits
corresponding to the E-State atom types originally defined by45, obtained from the
rcdk R package46. Fingerprint bits with zero variance across the dataset were
further removed, resulting in remaining 34 bits for the two sets of drugs.
Genomic descriptors. As genomic descriptors, we incorporated gene expression
profiles of the cancer cell lines, obtained from the rcellminer R package47. The gene
expression profiles were measured with five different platforms (four Affymetrix arrays
and an Agilent Whole Human Genome Oligo array) and a combined average z-score
was reported as a combined gene expression for a gene. To reduce the dimensionality
of the resulting feature matrix, we selected 0.5% of the genes with the highest variance
across the samples, resulting in 78 gene expression values for each cell line.
Cell lines. Early passage cells lines purchased from ATCC (HS-578T & Malme-
3M) and NCI-Frederick DCTD tumor/cell lines repository (SR & IGR-OV1) were
used for drug combination screening. The cell lines were maintained at 37 °C with
5% CO2 in a humidified incubator in their respective medium (see Supplementary
Table 4a). All the reagents were purchased from ThermoFisher Scientific. All the
cell lines were tested negative for mycoplasma. The test was based on the method
described by Choppa et al.48 and was performed as a service by the sample
management laboratory of THL Biobank, Helsinki, Finland.
Drug combination screening. The drug combination testing experimental design
was adopted from Gautam et al.49. Seven different concentrations in log3-fold dilution
of two drugs were combined with each other in 8 × 8 matrix formats. Please refer to
Supplementary Tables 4b and c for the dug information and combinations design,
respectively. The compounds were plated to black clear bottom 384-well plates
(Corning #3764) using an Echo 550 Liquid Handler (Labcyte). 100 μM benzethonium
chloride (BzCl2) and 0.1% dimethyl sulfoxide (DMSO) were used as positive and
negative controls, respectively. All subsequent liquid handling was performed using
MultiFlo FX multi-mode dispenser (BioTek). The pre-dispensed compounds were
dissolved in 5 μl of culture media and left in a plate shaker at room temperature for
30min. Twenty microliter cell suspension (please refer to Supplementary Table 4a for
cell line specific seeding densities) was dispensed in the drugged plates. After 72 h
incubation, 25 μl per well of CellTiter-Glo (Promega) reagent was added, and after
10 min of incubation at room temperature, luminescence (cell viability) was measured
using PheraStar plate reader (BMG Labtech).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
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